The Drug Administration Codes Quietly Denying Migraine Claims

A patient comes in for a scheduled CGRP infusion, part of an ongoing chronic migraine treatment plan. The clinical visit goes exactly as planned. Three weeks later, the claim comes back denied because the infusion sequencing code and the primary drug code were billed out of order, and the payer's system flagged it as a duplicate rather than a coordinated administration.

Drug administration billing for migraine and MS therapies is some of the most code-dense work in neurology, and small sequencing errors carry outsized financial consequences.

Why These Claims Are Uniquely Hard to Get Right

A single infusion encounter can involve a high-complexity evaluation, the primary infusion code, sequential or concurrent infusion add-on codes, and an NDC number specific to the exact drug and dose administered. Each element has its own billing rule, and missing sequencing or an absent NDC number is a common, avoidable trigger on claims that already represent thousands of dollars in revenue per encounter.

Neurology overall runs a claim denial rate of roughly 18%, nearly double the 5% to 10% average across other specialties, according to MGMA benchmarking data. Infusion and injectable therapy claims sit at the higher end of that range, because they combine two of the biggest denial drivers in the specialty at once: complex modifier rules and prior authorization requirements for high-cost drugs.

The Coding Change That Caught Practices Off Guard

CMS deleted ICD-10 code G35 for multiple sclerosis effective October 1, 2025, replacing it with codes that require the physician to document a specific MS phenotype and disease activity status. For MS treatment billing specifically, this is not a coder's problem to solve after the fact. A coder cannot assign the correct replacement code without the physician documenting the phenotype directly in the clinical note, which means any practice still relying on G35 on claims dated after October 2025 faces a mass denial event.

Botox for chronic migraine adds another layer entirely. Prior authorization requirements for chronic migraine Botox have gotten heavier heading into 2026, not lighter, and the authorization has to be tied to documented failure of first-line therapies before the payer will approve the injection series.

Getting the Sequence Right the First Time

Most infusion and injectable denials trace back to the same handful of preventable gaps. Catching them at the point of documentation, before the claim is generated, is far cheaper than fighting them after denial.

These are the specific checkpoints worth building into every infusion and injectable visit for migraine and MS patients, since the margin for sequencing error on these claims is unusually thin.

• Sequence primary and add-on infusion codes correctly. Out-of-order sequencing is one of the most common reasons a legitimate infusion claim gets flagged as a duplicate.
• Capture the NDC number for every administered drug. A missing NDC is an easy, entirely avoidable denial on claims that already carry significant dollar value.
• Document the specific MS phenotype and activity status at the visit. Post-G35, this cannot be reconstructed by a coder after the fact, it has to come from the physician's note.
• Tie Botox authorization to documented first-line treatment failure. Payers are tightening chronic migraine authorization requirements, and the failed-therapy history has to be visible in the chart.
• Verify authorization status before each infusion in a treatment series, not just the first. A lapsed authorization mid-series is a common, preventable denial trigger.
• Reconcile drug lot and dosage documentation with the billed units. A mismatch between documented dosage and billed units is a frequent audit flag on high-cost infusion therapies.

The Cost of Catching This Late

A denied infusion claim does not just delay payment. It often triggers a full re-review of the treatment series, since payers reasonably ask whether other encounters in the same series carry the same sequencing or documentation error. What starts as one denied claim can turn into a multi-visit audit, which is a far more expensive outcome than catching the NDC or sequencing gap at the first encounter.

Why This Belongs in the EMR Template, Not a Separate Spreadsheet

A neurology practice cannot rely on a biller catching sequencing errors after the fact. The fix has to live in the documentation template itself, prompting for NDC capture, phenotype documentation, and authorization status at the point of care.

ADS builds this level of specificity into its neurology-specific EHR and billing platform, part of a specialty practice portfolio spanning more than 30,000 physicians, helping practices hold a nearly 99% first-pass clean claim rate in a specialty where the average runs closer to 82%.

Migraine and MS drug therapy billing will not get simpler. But the errors driving most of these denials are entirely preventable at the point of documentation.

Want to see infusion and injectable billing built for neurology specifically?

Request a Live Demonstration and see how the Medics Suite handles NDC capture, sequencing, and MS phenotype documentation. A real person answers in under 2 minutes at 1-800-899-4237 ext 2264.

Sources: Medical Group Management Association denial rate benchmarking (mgma.com), CMS CY 2026 Physician Fee Schedule Final Rule (cms.gov), American Academy of Neurology (aan.com).